Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Edit functionality is currently unavailable.

Robert I. Haddad, M.D.

Co-Author

This page shows the publications co-authored by Robert Haddad and Lori Wirth.
Connection Strength

4.367
  1. Haddad R, Sherman SI, Shah JP, Wirth LJ. New frontiers and treatment paradigms for thyroid carcinoma. Clin Adv Hematol Oncol. 2014 Jul; 12(7 Suppl 14):3-21; quiz 22.
    View in: PubMed
    Score: 0.646
  2. Haddad RI, Nasr C, Bischoff L, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Goldner W, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McIver B, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sippel R, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Johnson-Chilla A, Hoffmann KG, Gurski LA. NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018. J Natl Compr Canc Netw. 2018 12; 16(12):1429-1440.
    View in: PubMed
    Score: 0.219
  3. Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli E, Powell S, Meister A, Shu X, Cheng JD, Haddad R. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. J Clin Oncol. 2017 May 10; 35(14):1542-1549.
    View in: PubMed
    Score: 0.195
  4. Haddad RI, Schlumberger M, Wirth LJ, Sherman EJ, Shah MH, Robinson B, Dutcus CE, Teng A, Gianoukakis AG, Sherman SI. Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine. 2017 Apr; 56(1):121-128.
    View in: PubMed
    Score: 0.193
  5. Haddad RI, Lydiatt WM, Ball DW, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McCaffrey JC, Moley JF, Parks L, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Hoffmann KG, Hughes M. Anaplastic Thyroid Carcinoma, Version 2.2015. J Natl Compr Canc Netw. 2015 Sep; 13(9):1140-50.
    View in: PubMed
    Score: 0.175
  6. Wirth LJ, Allen AM, Posner MR, Haddad RI, Li Y, Clark JR, Busse PM, Chan AW, Goguen LA, Norris CM, Annino DJ, Tishler RB. Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann Oncol. 2010 Feb; 21(2):342-347.
    View in: PubMed
    Score: 0.117
  7. Haddad R, Sonis S, Posner M, Wirth L, Costello R, Braschayko P, Allen A, Mahadevan A, Flynn J, Burke E, Li Y, Tishler RB. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer. 2009 Oct 01; 115(19):4514-23.
    View in: PubMed
    Score: 0.116
  8. Haddad RI, Tishler RB, Norris C, Goguen L, Balboni TA, Costello R, Wirth L, Lorch J, Andreozzi B, Annino D, Posner MR. Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 2009 Sep 20; 27(27):4448-53.
    View in: PubMed
    Score: 0.115
  9. Wirth LJ, Fogg M, Wang F, Lorch J, Haddad RI, Posner MR. Epstein-Barr virus (EBV)-specific immunotherapy in nasopharygneal carcinoma (NPC). J Clin Oncol. 2009 May 20; 27(15_suppl):6025.
    View in: PubMed
    Score: 0.113
  10. Lorch JH, Posner MR, Wirth LJ, Haddad RI. Induction chemotherapy in locally advanced head and neck cancer: a new standard of care? Hematol Oncol Clin North Am. 2008 Dec; 22(6):1155-63, viii.
    View in: PubMed
    Score: 0.110
  11. Lorch JH, Posner MR, Wirth LJ, Haddad RI. Seeking alternative biological therapies: the future of targeted molecular treatment. Oral Oncol. 2009 Apr-May; 45(4-5):447-53.
    View in: PubMed
    Score: 0.110
  12. Wirth LJ, Krane JF, Li Y, Othus M, Moran AE, Dorfman DM, Norris CM, Goguen L, Posner MR, Haddad RI, Bertagnolli MM. A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. Cancer Prev Res (Phila). 2008 Oct; 1(5):339-48.
    View in: PubMed
    Score: 0.108
  13. Tishler RB, Posner MR, Wirth LJ, Balboni T, Costello R, Goguen L, Annino D, Livada N, Norris CM, Haddad RI. Cetuximab added to docetaxel, cisplatin, 5-fluorouracil Induction chemotherapy (C-TPF) in patients with newly diagnosed locally advanced head and neck cancer: A phase I study. J Clin Oncol. 2008 May 20; 26(15_suppl):6001.
    View in: PubMed
    Score: 0.106
  14. Wirth LJ, Posner MR, Tishler RB, Haddad RI, Clark JR, Goguen L, Norris CM, Annino D, Costello R, Allen AM. Phase I study of panitumumab + chemoradiotherapy (CRT) for head and neck cancer (HNC). J Clin Oncol. 2008 May 20; 26(15_suppl):6007.
    View in: PubMed
    Score: 0.106
  15. Haddad R, Wirth L, Posner M. Emerging drugs for head and neck cancer. Expert Opin Emerg Drugs. 2006 Sep; 11(3):461-7.
    View in: PubMed
    Score: 0.094
  16. Goguen LA, Posner MR, Norris CM, Tishler RB, Wirth LJ, Annino DJ, Gagne A, Sullivan CA, Sammartino DE, Haddad RI. Dysphagia after sequential chemoradiation therapy for advanced head and neck cancer. Otolaryngol Head Neck Surg. 2006 Jun; 134(6):916-22.
    View in: PubMed
    Score: 0.092
  17. Haddad R, Tishler R, Wirth L, Norris CM, Goguen L, Sullivan C, O'Donnell L, Li Y, Posner M. Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2006 Jun; 132(6):678-81.
    View in: PubMed
    Score: 0.092
  18. Tishler RB, Posner MR, Norris CM, Mahadevan A, Sullivan C, Goguen L, Wirth LJ, Costello R, Case M, Stowell S, Sammartino D, Busse PM, Haddad RI. Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys. 2006 Jul 15; 65(4):1036-44.
    View in: PubMed
    Score: 0.092
  19. Goguen LA, Posner MR, Tishler RB, Wirth LJ, Norris CM, Annino DJ, Sullivan CA, Li Y, Haddad RI. Examining the need for neck dissection in the era of chemoradiation therapy for advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2006 May; 132(5):526-31.
    View in: PubMed
    Score: 0.092
  20. Haddad RI, Posner MR, Busse PM, Norris CM, Goguen LA, Wirth LJ, Blinder R, Krane JF, Tishler RB. Chemoradiotherapy for adenoid cystic carcinoma: preliminary results of an organ sparing approach. Am J Clin Oncol. 2006 Apr; 29(2):153-7.
    View in: PubMed
    Score: 0.091
  21. Haddad R, Allen A, Wirth L, Tishler R, Posner M. Integrating novel agents into the curative treatment of head and neck cancer. Expert Rev Anticancer Ther. 2006 Feb; 6(2):157-9.
    View in: PubMed
    Score: 0.090
  22. Wirth LJ, Haddad RI, Lindeman NI, Zhao X, Lee JC, Joshi VA, Norris CM, Posner MR. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2005 Oct 01; 23(28):6976-81.
    View in: PubMed
    Score: 0.088
  23. Wirth LJ, Moran AE, Krane JF, Weeks L, Norris CM, Goguen LA, Sullivan CA, Haddad RI, Posner MR, Bertagnolli MM. Pilot study of celecoxib in oral premalignant lesions (OPLs): Preliminary results. J Clin Oncol. 2005 Jun; 23(16_suppl):1025.
    View in: PubMed
    Score: 0.086
  24. Haddad RI, Tishler R, Wirth L, Norris C, Goguen L, Sullivan C, O'Donnell L, Li Y, Posner MR. Rate of complete pathological responses (pCR) to docetaxel/cisplatin/5-fluorouracil (TPF) induction chemotherapy in patients with newly diagnosed, locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 2005 Jun; 23(16_suppl):5511.
    View in: PubMed
    Score: 0.086
  25. Wirth LJ, Haddad RI, Wieczorek TJ, Faucher JL, Clark JR, Norris CM, Posner MR. Phase I study of gefitinib plus celecoxib in patients with metastatic and/or locally recurrent squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 2004 Jul 15; 22(14_suppl):5540.
    View in: PubMed
    Score: 0.081
  26. Guadagnolo BA, Tishler RB, Posner MR, Weeks L, Wirth LJ, Norris CM, Sullivan CA, Goguen L, Busse PM, Haddad RI. Organ preservation for patients treated with induction chemotherapy (IC) followed by radiation therapy (RT) or chemoradiation (CRT) for advanced stage squamous cell carcinoma of the larynx (SCCL). J Clin Oncol. 2004 Jul 15; 22(14_suppl):5600.
    View in: PubMed
    Score: 0.081
  27. Haddad RI, Gokhale AS, Wirth L, Weeks L, Faucher J, Hallar M, Cavacini LA, Posner MR. Interleukin-8 (IL-8) serum levels and squamous cell cancer of the head and neck (SCCHN). J Clin Oncol. 2004 Jul 15; 22(14_suppl):9716.
    View in: PubMed
    Score: 0.081
  28. Haddad R, Wirth L, Costello R, Weeks L, Posner M. Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. Semin Oncol. 2003 Dec; 30(6 Suppl 18):84-8.
    View in: PubMed
    Score: 0.078
  29. Haddad RI, Wirth L, Posner MR. Integration of chemotherapy in the curative treatment of locally advanced head and neck cancer. Expert Rev Anticancer Ther. 2003 Jun; 3(3):331-8.
    View in: PubMed
    Score: 0.075
  30. Wirth LJ, Haddad RI, Posner MR. Progress and perspectives in chemoprevention of head and neck cancer. Expert Rev Anticancer Ther. 2003 Jun; 3(3):339-55.
    View in: PubMed
    Score: 0.075
  31. Haddad R, Tishler RB, Norris CM, Mahadevan A, Busse P, Wirth L, Goguen LA, Sullivan CA, Costello R, Case MA, Posner MR. Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment. Oncologist. 2003; 8(1):35-44.
    View in: PubMed
    Score: 0.073
  32. Mahmood U, Bang A, Chen YH, Mak RH, Lorch JH, Hanna GJ, Nishino M, Manuszak C, Thrash EM, Severgnini M, Sanborn M, Sridharan V, Margalit DN, Tishler RB, Busse PM, Willers H, Mamon HJ, Yoo HJ, Pai SI, Wirth LJ, Haddad RI, Chau NG, Schoenfeld JD. A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. Int J Radiat Oncol Biol Phys. 2020 Aug 08.
    View in: PubMed
    Score: 0.062
  33. Hanna GJ, Busaidy NL, Chau NG, Wirth LJ, Barletta JA, Calles A, Haddad RI, Kraft S, Cabanillas ME, Rabinowits G, O'Neill A, Limaye SA, Alexander EK, Moore FD, Misiwkeiwicz K, Thomas T, Nehs M, Marqusee E, Lee SL, Jänne PA, Lorch JH. Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study. Clin Cancer Res. 2018 04 01; 24(7):1546-1553.
    View in: PubMed
    Score: 0.052
  34. Tuttle RM, Haddad RI, Ball DW, Byrd D, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, Lydiatt WM, McCaffrey J, Moley JF, Parks L, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ, Hoffmann KG, Hughes M. Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw. 2014 Dec; 12(12):1671-80; quiz 1680.
    View in: PubMed
    Score: 0.042
  35. Sher DJ, Balboni TA, Haddad RI, Norris CM, Posner MR, Wirth LJ, Goguen LA, Annino D, Tishler RB. Efficacy and toxicity of chemoradiotherapy using intensity-modulated radiotherapy for unknown primary of head and neck. Int J Radiat Oncol Biol Phys. 2011 Aug 01; 80(5):1405-11.
    View in: PubMed
    Score: 0.032
  36. Tuttle RM, Ball DW, Byrd D, Dilawari RA, Doherty GM, Duh QY, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey JC, Olson JA, Parks L, Ridge JA, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ. Thyroid carcinoma. J Natl Compr Canc Netw. 2010 Nov; 8(11):1228-74.
    View in: PubMed
    Score: 0.031
  37. Sher DJ, Haddad RI, Norris CM, Posner MR, Wirth LJ, Goguen LA, Annino D, Balboni T, Allen A, Tishler RB. Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer. Cancer. 2010 Oct 15; 116(20):4761-8.
    View in: PubMed
    Score: 0.031
  38. Tuttle RM, Ball DW, Byrd D, Daniels GH, Dilawari RA, Doherty GM, Duh QY, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson JA, Parks L, Ridge JA, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ. Medullary carcinoma. J Natl Compr Canc Netw. 2010 May; 8(5):512-30.
    View in: PubMed
    Score: 0.030
  39. Posner MR, Norris CM, Wirth LJ, Shin DM, Cullen KJ, Winquist EW, Blajman CR, Mickiewicz EA, Frenette GP, Plinar LF, Cohen RB, Steinbrenner LM, Freue JM, Gorbunova VA, Tjulandin SA, Raez LE, Adkins DR, Tishler RB, Roessner MR, Haddad RI. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol. 2009 May; 20(5):921-7.
    View in: PubMed
    Score: 0.028
  40. Caglar HB, Tishler RB, Othus M, Burke E, Li Y, Goguen L, Wirth LJ, Haddad RI, Norris CM, Court LE, Aninno DJ, Posner MR, Allen AM. Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008 Nov 15; 72(4):1110-8.
    View in: PubMed
    Score: 0.026
  41. Posner MR, Norris CM, Tishler RB, Wirth LJ, Haddad RI. Sequential therapy for locally advanced larynx and hypopharynx cancer: Subgroup analysis from the TAX 324 Study. J Clin Oncol. 2008 May 20; 26(15_suppl):6031.
    View in: PubMed
    Score: 0.026
  42. Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, Fidias PH, Temel JS, Gurubhagavatula S, Heist RS, Clark JR, Lynch TJ. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid. 2008 Mar; 18(3):317-23.
    View in: PubMed
    Score: 0.026
  43. Guadagnolo BA, Haddad RI, Posner MR, Weeks L, Wirth LJ, Norris CM, Sullivan CA, Goguen L, Busse PM, Tishler R. Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer. Am J Clin Oncol. 2005 Aug; 28(4):371-8.
    View in: PubMed
    Score: 0.022
  44. Gokhale AS, Haddad RI, Cavacini LA, Wirth L, Weeks L, Hallar M, Faucher J, Posner MR. Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck. Oral Oncol. 2005 Jan; 41(1):70-6.
    View in: PubMed
    Score: 0.021
  45. Posner MR, Haddad RI, Wirth L, Norris CM, Goguen LA, Mahadevan A, Sullivan C, Tishler RB. Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin Oncol. 2004 Dec; 31(6):778-85.
    View in: PubMed
    Score: 0.021
  46. Sullivan CA, Jaklitsch MT, Haddad R, Goguen LA, Gagne A, Wirth LJ, Posner MR, Tishler RB, Norris CM. Endoscopic management of hypopharyngeal stenosis after organ sparing therapy for head and neck cancer. Laryngoscope. 2004 Nov; 114(11):1924-31.
    View in: PubMed
    Score: 0.021
  47. Tishler RB, Haddad RI, Norris CM, Sullivan C, Mahadevan A, Wirth L, Goguen L, Nixon A, Stowell S, Posner MR. A phase I/II study of docetaxel (D) and concomitant boost radiation (CBR) for patients with squamous cell cancer of the head and neck (SCCHN) following induction chemotherapy (IC). J Clin Oncol. 2004 Jul 15; 22(14_suppl):5548.
    View in: PubMed
    Score: 0.020
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.